Associated Papers
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Westenberger A et al.
Brain : a Journal of Neurology, 2024
39087914 (PubMed )
Supplement: awae188_supplementary_data.zip › awae188_Supplementary_Table_6.f..xlsx › Sheet1
The characteristics of FBXO7 and its role in human diseases.
Zhong Y et al.
Gene, 2023
Identification of sixteen novel candidate genes for late onset Parkinson's disease.
Gialluisi A et al.
Molecular Neurodegeneration, 2021
34148545 (PubMed )
Supplement: 13024_2021_455_MOESM1_ESM.pdf
From PARK9 to SPG78: The clinical spectrum of ATP13A2 mutations.
Erro R et al.
Parkinsonism & Related Disorders, 2019
A Comprehensive Atlas of E3 Ubiquitin Ligase Mutations in Neurological Disorders.
George AJ et al.
Frontiers in Genetics, 2018
29491882 (PubMed )
Supplement: Table1.xlsx › Sheet1
Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson's disease (PD).
Zhou ZD et al.
Molecular Brain, 2016
Systematic mutational analysis of FBXO7 in a Parkinson's disease population from southern Spain.
Gómez-Garre P et al.
Neurobiology of Aging, 2014
Beyond ubiquitination: the atypical functions of Fbxo7 and other F-box proteins.
Nelson DE et al.
Open Biology, 2013
Altered apoptosis regulation in Kufor-Rakeb syndrome patients with mutations in the ATP13A2 gene.
Radi E et al.
Journal of Cellular and Molecular Medicine, 2012
Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability.
Santoro L et al.
Neurogenetics, 2011
Select a paper to view details